KBKonstantinos Boulias

Konstantinos Boulias

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Konstantinos Boulias has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Type 1 immunity linked to CMV exposure improves long-term survival in sepsis without shock

    by Wei Qi, Nuzat Zaman, Alexis Rooney, Caroline B.M. Porter, Konstantinos Boulias, Sarah Naz-McLean, Joshua Pickard, Marla Glean, Ndongwa Pemba, Kastin Pan, et al.

    Dysregulated immune responses are at the core of sepsis pathology and can drive both acute organ dysfunction and long-term morbidity and mortality. To better understand the association between specific immune histories, perturbations and sepsis outcomes, we combined immune phenotyping, functional cytokine production assays and antibody repertoire profiling. While sepsis immune profiles were highly heterogeneous, we identified a strong association between the frequency of CXCR3-expressing CD4 memory T cells at time of enrollment and six-month survival in sepsis without shock. Surprisingly, the same population was linked to improved organ function trajectories in septic shock patients but did not influence six-month survival, highlighting the importance of considering physiological states to define immune predictors. Finally, phage display profiling revealed that these Th1 cells were generally expanded in CMV-seropositive individuals, suggesting that previous and latent infections may modulate sepsis outcomes.

  • Open Access

    Reversible m 6 Am methylation of snRNA by FTO controls morphine reward and tolerance without altering analgesia

    by Shan Liu, Ayma F. Malik, Raymond Chien, Jianheng Liu, Luke S. Nicholson, Jin Xu, Kimia Didehvar, Vipin Rai, Valerie P. Le Rouzic, Arlene Martínez-Rivera, et al.

    SUMMARY: Mu opioids, such as morphine, are effective analgesics, but their reward and tolerance drive opioid use disorder. A major goal is to achieve analgesia without these harmful effects. Here we show that morphine reward and tolerance require the RNA demethylase FTO. Genetic depletion and pharmacologic inhibition of FTO each reduced morphine reward, measured by conditioned-place preference, and reduced antinociceptive tolerance to morphine and fentanyl, without altering analgesia. Although FTO is known to erase m 6 A on mRNA, we found no effect of FTO depletion on m 6 A sites, but markedly increased levels of m 6 Am on snRNA. The effects of FTO depletion were suppressed in mice that cannot make m 6 Am, supporting the role of m 6 Am in morphine reward and tolerance. We show that FTO depletion regulates a gene expression network linked to morphine signaling. FTO inhibitors may therefore provide useful adjuvants to mu opioids in pain management and treatment of opioid use disorder.


  • Open Access

    18S rRNA methyltransferases DIMT1 and BUD23 drive intergenerational hormesis

    by Noa Liberman, M. Hafiz Rothi, Maxim V. Gerashchenko, Christiane Zorbas, Konstantinos Boulias, Fiona G. MacWhinnie, Albert Kejun Ying, Anya Flood Taylor, Joseph Al Haddad, Hiroki Shibuya, et al.


  • Open Access

    Messenger RNA cap methylation by PCIF1 attenuates the interferon-β induced antiviral state

    by Michael A. Tartell, Konstantinos Boulias, Gabriela Brunsting Hoffmann, Eric Lieberman Greer, Sean P. J. Whelan

    Interferons induce cell intrinsic responses associated with resistance to viral infection. To overcome the suppressive action of interferons and their downstream effectors viruses have evolved diverse mechanisms. Working with vesicular stomatitis virus (VSV) we report a role for the host cell N6-adenosine mRNA cap-methylase, phosphorylated C-terminal domain interacting factor 1 (PCIF1), in attenuating the antiviral activity of interferon-β. Using cell based and in vitro biochemical assays we demonstrate that PCIF1 efficiently modifies VSV mRNA cap structures to m 7 Gpppm 6 A m , and we identify the cis -acting elements required for this modification. Under basal conditions, N6-methylation of VSV mRNA cap structures is functionally inert with regard to mRNA stability, translation and viral infectivity. Induction of an antiviral state by treatment of cells with interferon-β prior to infection uncovered a functional role for PCIF1 in attenuation of the antiviral response. Cells lacking PCIF1 or expressing a catalytically inactive PCIF1, exhibit an augmented effect of interferon-β in the inhibition of viral replication and gene expression. This work identifies a function of PCIF1 and cap-proximal m 6 A m in attenuation of the host response to VSV infection that likely extends to other viruses. Significance: The cap structure present at the 5’ end of eukaryotic mRNAs regulates RNA stability, translation, and marks mRNA as self, thereby impeding recognition by the innate immune system. Cellular transcripts beginning with adenosine are additionally modified at the N6 position of the 2’-O methylated cap-proximal residue by the methyltransferase PCIF1 to m 7 Gpppm 6 A m . We define a function for this N6-adenosine methylation in attenuating the interferon-β mediated suppression of viral infection. Cells lacking PCIF1, or defective in its enzymatic activity, augment the cell intrinsic suppressive effect of interferon-β treatment on vesicular stomatitis virus gene expression. VSV mRNAs are efficiently methylated by PCIF1, suggesting this contributes to viral evasion of innate immune suppression.

  • Open Access

    Coping with darkness: The adaptive response of marine picocyanobacteria to repeated light energy deprivation

    by Allison Coe, Steven J. Biller, Elaina Thomas, Konstantinos Boulias, Christina Bliem, Aldo Arellano, Keven Dooley, Anna N. Rasmussen, Kristen LeGault, Tyler J. O’kEefe, et al.

    The picocyanobacteria Prochlorococcus and Synechococcus are found throughout the ocean’s euphotic zone, where the daily light:dark cycle drives their physiology. Periodic deep mixing events can, however, move cells below this zone, depriving them of light for extended periods of time. Here we demonstrate that Prochlorococcus and Synechococcus can adapt to tolerate repeated periods of light energy deprivation. Cyanobacterial cultures kept in the dark for 3 days and then returned to the light initially required 18-26 days to resume growth, but after multiple rounds of dark exposure the strains began to regrow after only 1-2 days. This dark-tolerant phenotype was stable and heritable; cultures retained the trait across at least 18-21 generations even when grown in a standard 13:11 light:dark cycle. We found no genetic differences between the dark-tolerant and parental strains of Prochlorococcus NATL2A, indicating that an epigenetic change is responsible for the adaptation. To begin to explore this possibility, we asked whether DNA methylation – an epigenetic mechanism in bacteria – occurs in Prochlorococcus . LC-MS/MS analysis showed that while DNA methylations, including 6mA and 5mC, are found in some other Prochlorococcus strains, no methylations were detected in either the parental or dark-tolerant strain used in our experiments –i.e. the NATL2A strain. These findings suggest that Prochlorococcus utilizes a yet-to-be-determined epigenetic mechanism to adapt to the stress of extended light energy deprivation.